Analysis of Survival Data in Thalassemia Patients in Shiraz, Iran

Overview

Journal Epidemiol Health

Specialty Public Health

Date 2015 Jul 28

PMID 26212506

Citations 12

Authors

Abdolreza Rajaeefard

Mahmoud Hajipour

Hamid Reza Tabatabaee

Jafar Hassanzadeh

Shahab Rezaeian

Zahra Moradi

Mehdi Sharafi

Mohsen Shafiee

Ali Semati

Sanaz Safaei

Maryam Soltani

Affiliations

Soon will be listed here.

Abstract

Objectives: The survival rate of thalassemia patients has not been conclusively established, and the factors associated with survival remain unclear. This study aimed to determine the survival rate of thalassemia among patients in southern Iran and to identify the factors associated with mortality from thalassemia.

Methods: This retrospective cohort study was conducted based on a retrospective review of the medical records of 911 beta-thalassemia patients in 2014. Data analysis was conducted using the Kaplan-Meier method and Cox regression analysis.

Results: Overall, 212 patients (23.3%) died, and 26.8% had thalassemia intermedia. The 20-year, 40-year, and 60-year survival rates were 85%, 63%, and 54%, respectively. Both crude and adjusted analyses found that education, marital status, ferritin levels, and comorbidities were related to mortality.

Conclusions: Sociodemographic and hematological factors were found to be significantly associated with the survival rate of thalassemia. Addressing these factors may help healthcare providers and physicians to provide the best possible care and to improve the survival rate.

Citing Articles

Mortality and complications in Omani patients with beta-thalassemia major: a long-term follow-up study.

Daar S, Al-Naamani K, De Sanctis V, Al Rahbi S, Al Zadjali S, Khan H Acta Biomed. 2023; 94(4):e2023191.

PMID: 37539594 PMC: 10440768. DOI: 10.23750/abm.v94i5.14856.

Atrial Fibrillation in β-Thalassemia: Overview of Mechanism, Significance and Clinical Management.

Malagu M, Marchini F, Fiorio A, Sirugo P, Clo S, Mari E Biology (Basel). 2022; 11(1).

PMID: 35053146 PMC: 8772694. DOI: 10.3390/biology11010148.

Economic burden in the management of transfusion-dependent thalassaemia patients in Malaysia from a societal perspective.

Shafie A, Wong J, Mohd Ibrahim H, Mohammed N, Chhabra I Orphanet J Rare Dis. 2021; 16(1):157.

PMID: 33827621 PMC: 8028190. DOI: 10.1186/s13023-021-01791-8.

Eradication of hepatitis C virus infection in thalassemia patients in Iran using various treatment strategies.

Moghimbeygi M, Alavian S J Virus Erad. 2020; 6(3):100006.

PMID: 33251024 PMC: 7646675. DOI: 10.1016/j.jve.2020.100006.

Changing patterns in the epidemiology of β-thalassemia.

Kattamis A, Forni G, Aydinok Y, Viprakasit V Eur J Haematol. 2020; 105(6):692-703.

PMID: 32886826 PMC: 7692954. DOI: 10.1111/ejh.13512.

References

Weatherall D, Clegg J . Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001; 79(8):704-12. PMC: 2566499. View

Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini M, Del Vecchio G . Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004; 89(10):1187-93. View

Samavat A, Modell B . Iranian national thalassaemia screening programme. BMJ. 2004; 329(7475):1134-7. PMC: 527686. DOI: 10.1136/bmj.329.7475.1134. View

Borgna-Pignatti C, Cappellini M, De Stefano P, Del Vecchio G, Forni G, Gamberini M . Survival and complications in thalassemia. Ann N Y Acad Sci. 2005; 1054:40-7. DOI: 10.1196/annals.1345.006. View

Telfer P, Coen P, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E . Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica. 2006; 91(9):1187-92. View

Kosaryan M, Vahidshahi K, Karami H, Forootan M, Ahangari M . Survival of thalassemic patients referred to the Boo Ali Sina Teaching Hospital, Sari, Iran. Hemoglobin. 2007; 31(4):453-62. DOI: 10.1080/03630260701641294. View

Toumba M, Sergis A, Kanaris C, Skordis N . Endocrine complications in patients with Thalassaemia Major. Pediatr Endocrinol Rev. 2007; 5(2):642-8. View

Khorasani G, Kosaryan M, Vahidshahi K, Shakeri S, Nasehi M . Results of the national program for prevention of beta-thalassemia major in the Iranian Province of Mazandaran. Hemoglobin. 2008; 32(3):263-71. DOI: 10.1080/03630260802004269. View

Modell B, Darlison M . Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008; 86(6):480-7. PMC: 2647473. DOI: 10.2471/blt.06.036673. View

10.

Roudbari M, Soltani-Rad M, Roudbari S . The survival analysis of beta thalassemia major patients in South East of Iran. Saudi Med J. 2008; 29(7):1031-5. View

11.

Kosaryan M, Vahidshahi K, Siami R, Nazari M, Karami H, Ehteshami S . Knowledge, attitude, and practice of reproductive behavior in Iranian minor thalassemia couples. Saudi Med J. 2009; 30(6):835-9. View

12.

Hein M, Schubauer-Berigan M, Deddens J . Evaluating bias from birth-cohort effects in the age-based cox proportional hazards model. Epidemiology. 2011; 22(2):249-56. DOI: 10.1097/EDE.0b013e3182093912. View

13.

Miri-Moghaddam E, Zadeh-Vakili A, Rouhani Z, Naderi M, Eshghi P, Khazaei Feizabad A . Molecular basis and prenatal diagnosis of β-thalassemia among Balouch population in Iran. Prenat Diagn. 2011; 31(8):788-91. DOI: 10.1002/pd.2767. View

14.

Safizadeh H, Farahmandinia Z, Nejad S, Pourdamghan N, Araste M . Quality of life in patients with thalassemia major and intermedia in kerman-iran (I.R.). Mediterr J Hematol Infect Dis. 2012; 4(1):e2012058. PMC: 3499998. DOI: 10.4084/MJHID.2012.058. View

15.

Haghpanah S, Johari S, Parand S, Bordbar M, Karimi M . Family planning practices in families with children affected by β-thalassemia major in Southern Iran. Hemoglobin. 2012; 37(1):74-9. DOI: 10.3109/03630269.2012.745419. View

16.

Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2095-128. PMC: 10790329. DOI: 10.1016/S0140-6736(12)61728-0. View

17.

Hadipour Dehshal M, Ahmadvand A, Yousefi Darestani S, Manshadi M, Abolghasemi H . Secular trends in the national and provincial births of new thalassemia cases in Iran from 2001 to 2006. Hemoglobin. 2013; 37(2):124-37. DOI: 10.3109/03630269.2013.772062. View

18.

Gollo G, Savioli G, Balocco M, Venturino C, Boeri E, Costantini M . Changes in the quality of life of people with thalassemia major between 2001 and 2009. Patient Prefer Adherence. 2013; 7:231-6. PMC: 3615844. DOI: 10.2147/PPA.S42133. View

19.

Zamani R, Khazaei S, Rezaeian S . Survival analysis and its associated factors of Beta thalassemia major in hamadan province. Iran J Med Sci. 2015; 40(3):233-9. PMC: 4430885. View

20.

Asadi-Pooya A, Doroudchi M . Thalassemia major and consanguinity in Shiraz city, Iran. Turk J Haematol. 2016; 21(3):127-30. View